| Abstrakt: |
A recent study conducted by researchers at the University of Louisville examined the effects of sacubitril/valsartan on patients with heart failure with preserved ejection fraction (HFpEF). The study analyzed data from four randomized trials involving a total of 8,129 participants. The findings showed that sacubitril/valsartan was associated with a reduction in NT-proBNP levels and an improvement in the quality of life for patients with HFpEF. However, there were no significant differences observed in HF hospitalization, cardiovascular mortality, all-cause mortality, or NYHA class improvement or worsening between the sacubitril/valsartan and comparator groups. The researchers concluded that sacubitril/valsartan may have potential benefits for patients with HFpEF, but further research is needed to determine its clinical outcomes. [Extracted from the article] |
